Literature DB >> 24629333

Viruses for tumor therapy.

John Bell1, Grant McFadden2.   

Abstract

Oncolytic virotherapy exploits live viruses with selective tropism for cancerous cells and tissues to treat cancer. As discussed here, the field has progressed considerably as a result of both the successes and failures of previous and on-going clinical trials for various cancers. These studies indicate that oncolytic viruses are remarkably safe and more efficacious when virus replication stimulates sustained antitumor immune responses. In the future, virotherapy should be combined with immunomodulatory reagents that target immune tolerance to established cancers.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24629333      PMCID: PMC3963258          DOI: 10.1016/j.chom.2014.01.002

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  29 in total

Review 1.  Oncolytic vaccines.

Authors:  Noura B Elsedawy; Stephen J Russell
Journal:  Expert Rev Vaccines       Date:  2013-10       Impact factor: 5.217

Review 2.  Intelligent design: combination therapy with oncolytic viruses.

Authors:  Kathryn Ottolino-Perry; Jean-Simon Diallo; Brian D Lichty; John C Bell; J Andrea McCart
Journal:  Mol Ther       Date:  2009-12-22       Impact factor: 11.454

Review 3.  Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus.

Authors:  Masmudur M Rahman; Gerard J Madlambayan; Christopher R Cogle; Grant McFadden
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-07       Impact factor: 7.638

Review 4.  Oncolytic viruses for induction of anti-tumor immunity.

Authors:  Alex W Tong; Neil Senzer; Vincenzo Cerullo; Nancy Smyth Templeton; Akseli Hemminki; John Nemunaitis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 5.  Live viruses to treat cancer.

Authors:  Oliver Donnelly; Kevin Harrington; Alan Melcher; Hardev Pandha
Journal:  J R Soc Med       Date:  2013-07-03       Impact factor: 5.344

Review 6.  Recent clinical experience with oncolytic viruses.

Authors:  O G Donnelly; F Errington-Mais; R Prestwich; K Harrington; H Pandha; R Vile; A A Melcher
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 7.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

Review 8.  Oncolytic virus therapy for cancer: the first wave of translational clinical trials.

Authors:  Manish R Patel; Robert A Kratzke
Journal:  Transl Res       Date:  2013-01-10       Impact factor: 7.012

Review 9.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

10.  Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Authors:  Emily K Mader; Greg Butler; Sean C Dowdy; Andrea Mariani; Keith L Knutson; Mark J Federspiel; Stephen J Russell; Evanthia Galanis; Allan B Dietz; Kah-Whye Peng
Journal:  J Transl Med       Date:  2013-01-24       Impact factor: 5.531

View more
  69 in total

1.  Oncolytic Poxviruses.

Authors:  Winnie M Chan; Grant McFadden
Journal:  Annu Rev Virol       Date:  2014-09-01       Impact factor: 10.431

Review 2.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

3.  Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Authors:  Rūta Veinalde; Christian Grossardt; Laura Hartmann; Marie-Claude Bourgeois-Daigneault; John C Bell; Dirk Jäger; Christof von Kalle; Guy Ungerechts; Christine E Engeland
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

4.  Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.

Authors:  Nanmeng Yu; Shelby Puckett; Peter A Antinozzi; Scott D Cramer; Douglas S Lyles
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

Review 5.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

6.  Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation.

Authors:  Xiaoli Wang; Sytse J Piersma; Jabari I Elliott; John M Errico; Maria D Gainey; Liping Yang; Christopher A Nelson; Wayne M Yokoyama; Daved H Fremont
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-01       Impact factor: 11.205

7.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

8.  Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.

Authors:  Patrick Kellish; Daniil Shabashvili; Masmudur M Rahman; Akbar Nawab; Maria V Guijarro; Min Zhang; Chunxia Cao; Nissin Moussatche; Theresa Boyle; Scott Antonia; Mary Reinhard; Connor Hartzell; Michael Jantz; Hiren J Mehta; Grant McFadden; Frederic J Kaye; Maria Zajac-Kaye
Journal:  J Clin Invest       Date:  2019-04-29       Impact factor: 14.808

9.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

Review 10.  The therapeutic effect of death: Newcastle disease virus and its antitumor potential.

Authors:  Sara Cuadrado-Castano; Maria T Sanchez-Aparicio; Adolfo García-Sastre; Enrique Villar
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.